title: Stem celltherapy for ischemic heart failure.
abstract: As the prevalence and incidence of ischemic heart disease continue to increase, so does interest in ischemic heart failure management. Limitations of current therapies have led to research aimed at regenerating and repairing ischemically damaged myocardium through stem-cell therapy. Cell types being evaluated include embryonic stem cells, fetal and neonatal cardiomyocytes, skeletal myoblasts, bone marrow stem cells, peripheral blood CD34+ cells, endothelial progenitor cells, cardiac progenitor cells, and fibroblasts. Preclinical animal studies and promising early results of clinical trials now under way suggest that stem-cell therapy may soon become an important new tool in heart failure management.
authors.affiliation: Heart Failure Research Laboratory, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA. Doreen.Rosenstrauch@uth.tmc.edu
authors.forename: Doreen
authors.initials: D
authors.lastname: Rosenstrauch
authors.forename: Gregor
authors.initials: G
authors.lastname: Poglajen
authors.forename: Nina
authors.initials: N
authors.lastname: Zidar
authors.forename: Igor D
authors.initials: ID
authors.lastname: Gregoric
mesh_terms: D006333:Heart Failure / Q000209:etiology / Q000601:surgery*; D006801:Humans; D017202:Myocardial Ischemia / Q000150:complications*; D033581:Stem Cell Transplantation / Q000379:methods*; D016896:Treatment Outcome